ES2646438T3 - Accs para uso en la aceleración de la curación de lesiones del tejido conectivo - Google Patents
Accs para uso en la aceleración de la curación de lesiones del tejido conectivo Download PDFInfo
- Publication number
- ES2646438T3 ES2646438T3 ES12734721.9T ES12734721T ES2646438T3 ES 2646438 T3 ES2646438 T3 ES 2646438T3 ES 12734721 T ES12734721 T ES 12734721T ES 2646438 T3 ES2646438 T3 ES 2646438T3
- Authority
- ES
- Spain
- Prior art keywords
- accs
- cells
- healing
- accelerating
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000035876 healing Effects 0.000 title claims abstract description 8
- 210000002808 connective tissue Anatomy 0.000 title description 6
- 230000003902 lesion Effects 0.000 title description 6
- 102000004127 Cytokines Human genes 0.000 claims abstract description 12
- 108090000695 Cytokines Proteins 0.000 claims abstract description 12
- 210000001691 amnion Anatomy 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 208000021945 Tendon injury Diseases 0.000 claims abstract description 5
- 210000002435 tendon Anatomy 0.000 claims abstract description 5
- 206010061223 Ligament injury Diseases 0.000 claims abstract description 4
- 102100021283 1-aminocyclopropane-1-carboxylate synthase-like protein 1 Human genes 0.000 claims abstract 8
- 101000675558 Homo sapiens 1-aminocyclopropane-1-carboxylate synthase-like protein 1 Proteins 0.000 claims abstract 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- -1 antibodies Substances 0.000 claims description 4
- 238000011277 treatment modality Methods 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 208000034656 Contusions Diseases 0.000 claims description 2
- 208000010040 Sprains and Strains Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229940121357 antivirals Drugs 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 238000000554 physical therapy Methods 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 238000009207 exercise therapy Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 4
- 210000000646 extraembryonic cell Anatomy 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 208000000491 Tendinopathy Diseases 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000002993 trophoblast Anatomy 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000002219 extraembryonic membrane Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 102100022987 Angiogenin Human genes 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000013201 Stress fracture Diseases 0.000 description 1
- 208000023835 Tendon disease Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 208000013515 tendinosis Diseases 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161460913P | 2011-01-10 | 2011-01-10 | |
| US201161460913P | 2011-01-10 | ||
| PCT/US2012/000017 WO2012096796A1 (en) | 2011-01-10 | 2012-01-07 | Methods for accelerating the healing of connective tissue injuries and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2646438T3 true ES2646438T3 (es) | 2017-12-13 |
Family
ID=46455423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12734721.9T Active ES2646438T3 (es) | 2011-01-10 | 2012-01-07 | Accs para uso en la aceleración de la curación de lesiones del tejido conectivo |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8642547B2 (enExample) |
| EP (1) | EP2663637B1 (enExample) |
| JP (1) | JP6041812B2 (enExample) |
| CN (1) | CN103298927B (enExample) |
| CA (1) | CA2823689C (enExample) |
| ES (1) | ES2646438T3 (enExample) |
| WO (1) | WO2012096796A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015171880A1 (en) * | 2014-05-08 | 2015-11-12 | The University Of Florida Research Foundation, Inc. | Sustained release angiogenesis modulating compositions and methods for induction and modulation of angiogenesis |
| WO2018123628A1 (ja) * | 2016-12-28 | 2018-07-05 | ロート製薬株式会社 | 細胞医薬組成物、疾患治療用キット及び細胞懸濁用溶液 |
| BR112022000502A2 (pt) * | 2019-08-09 | 2022-03-15 | Axolotl Biologix Inc | Método para preparar uma composição derivada de âmnion humano acelular configurada para uso terapêutico, método para tratar um sujeito sofrendo de doença articular degenerativa, e composição derivada de âmnion humano |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8803697D0 (en) * | 1988-02-17 | 1988-03-16 | Deltanine Research Ltd | Clinical developments using amniotic membrane cells |
| DE69714035T2 (de) * | 1997-08-14 | 2003-03-06 | Sulzer Innotec Ag, Winterthur | Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren |
| AU2002251935B2 (en) * | 2001-02-14 | 2007-11-29 | Celularity Inc. | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| GB0113697D0 (en) * | 2001-06-06 | 2001-07-25 | Smith & Nephew | Fixation devices for tissue repair |
| US7473816B2 (en) * | 2004-05-18 | 2009-01-06 | Lohmann & Rauscher, Inc. | Multilayer moisture management fabric |
| US20060222634A1 (en) | 2005-03-31 | 2006-10-05 | Clarke Diana L | Amnion-derived cell compositions, methods of making and uses thereof |
| US8153430B2 (en) | 2005-03-31 | 2012-04-10 | Stemnion, Inc. | Methods related to surgery |
| US8241902B2 (en) | 2006-01-11 | 2012-08-14 | Technion Research & Development Foundation Ltd. | Preparation of adult stem cell-derived connective tissue progenitors |
| US8871198B2 (en) * | 2006-03-29 | 2014-10-28 | Stemnion, Inc. | Methods related to wound healing |
| US8475788B2 (en) * | 2006-06-14 | 2013-07-02 | Stemnion, Inc. | Methods of treating spinal cord injury and minimizing scarring |
| US8221741B2 (en) | 2007-01-17 | 2012-07-17 | Marshall Vivienne S | Methods for modulating inflammatory and/or immune responses |
| JPWO2008102568A1 (ja) * | 2007-02-22 | 2010-05-27 | 株式会社Ｐｇリサーチ | 骨軟骨形成促進剤 |
| EP2139497B1 (en) * | 2007-04-13 | 2013-11-06 | Stemnion, INC. | Methods for treating nervous system injury and disease |
| US20080279825A1 (en) * | 2007-05-10 | 2008-11-13 | Malinin Theodore I | Cartilage material |
| JP2010536851A (ja) | 2007-08-22 | 2010-12-02 | ステムニオン，インコーポレイテッド | 新規の細胞性因子含有溶液組成物 |
| WO2010012025A1 (en) * | 2008-07-28 | 2010-02-04 | Monash University | Amnion epithelial cells for the treatment of degenerative disc disease |
| US20100215731A1 (en) * | 2009-02-20 | 2010-08-26 | Maastricht University | Method for improving cartilage repair and/or preventing cartilage degeneration in a joint |
-
2012
- 2012-01-07 CN CN201280004911.0A patent/CN103298927B/zh active Active
- 2012-01-07 US US13/374,674 patent/US8642547B2/en active Active
- 2012-01-07 JP JP2013548446A patent/JP6041812B2/ja active Active
- 2012-01-07 WO PCT/US2012/000017 patent/WO2012096796A1/en not_active Ceased
- 2012-01-07 EP EP12734721.9A patent/EP2663637B1/en active Active
- 2012-01-07 ES ES12734721.9T patent/ES2646438T3/es active Active
- 2012-01-07 CA CA2823689A patent/CA2823689C/en active Active
-
2013
- 2013-03-05 US US13/785,139 patent/US8883136B2/en active Active
-
2014
- 2014-10-28 US US14/525,654 patent/US9623089B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8883136B2 (en) | 2014-11-11 |
| US20130183285A1 (en) | 2013-07-18 |
| CA2823689A1 (en) | 2012-07-19 |
| CN103298927B (zh) | 2016-03-09 |
| JP2014501778A (ja) | 2014-01-23 |
| WO2012096796A1 (en) | 2012-07-19 |
| JP6041812B2 (ja) | 2016-12-14 |
| US8642547B2 (en) | 2014-02-04 |
| US20160114008A1 (en) | 2016-04-28 |
| US20120177633A1 (en) | 2012-07-12 |
| CA2823689C (en) | 2019-10-08 |
| EP2663637A4 (en) | 2014-08-06 |
| CN103298927A (zh) | 2013-09-11 |
| EP2663637A1 (en) | 2013-11-20 |
| US9623089B2 (en) | 2017-04-18 |
| EP2663637B1 (en) | 2017-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2684599T3 (es) | Células adherentes de la placenta y uso de las mismas en el tratamiento de enfermedades | |
| Ratajczak et al. | New advances in stem cell research: practical implications for regenerative medicine | |
| AU2021203074A1 (en) | Placental-derived stem cells to restore the regenerative engine, correct proteomic defects and extend lifespan | |
| CA2837871C (en) | Treatment of pain using placental stem cells | |
| ES2628129T3 (es) | Tratamiento de la enfermedad vascular periférica utilizando células derivadas del posparto | |
| ES2963038T3 (es) | Uso de células T de memoria central antitercero | |
| Salehi et al. | Epidermal neural crest stem cell transplantation as a promising therapeutic strategy for ischemic stroke | |
| Longhini et al. | Peripheral blood-derived mesenchymal stem cells demonstrate immunomodulatory potential for therapeutic use in horses | |
| Dolezalova et al. | Pig models of neurodegenerative disorders: utilization in cell replacement‐based preclinical safety and efficacy studies | |
| Jones et al. | Upregulating CXCR4 in human fetal mesenchymal stem cells enhances engraftment and bone mechanics in a mouse model of osteogenesis imperfecta | |
| JP2014507390A (ja) | 胎盤幹細胞を用いる脊髄損傷及び外傷性脳損傷の治療 | |
| Kropp et al. | Assisted reproductive technologies in the common marmoset: an integral species for developing nonhuman primate models of human diseases | |
| Sultana et al. | Current status of canine umbilical cord blood‐derived mesenchymal stem cells in veterinary medicine | |
| Nowak-Imialek et al. | Oct4-enhanced green fluorescent protein transgenic pigs: a new large animal model for reprogramming studies | |
| Buckenmeyer et al. | A bioengineered in situ ovary (ISO) supports follicle engraftment and live-births post-chemotherapy | |
| Ivanovska et al. | Immunophenotypical characterization of canine mesenchymal stem cells from perivisceral and subcutaneous adipose tissue by a species-specific panel of antibodies | |
| Sahoo et al. | Isolation, culture, characterization, and osteogenic differentiation of canine endometrial mesenchymal stem cell | |
| Rudnitsky et al. | Mesenchymal stem cells and their derivatives as potential longevity-promoting tools | |
| CA2991053A1 (en) | Humanized skeletal muscle | |
| Gehrke et al. | Amorphus globosus foetuses in Polish Holstein cattle: anatomical, histological, and genetic studies | |
| Chang et al. | The canine epiphyseal-derived mesenchymal stem cells are comparable to bone marrow derived-mesenchymal stem cells | |
| CN116801891A (zh) | 用于预防或治疗炎性疾病或疼痛的包含表达ptx-3、timp1和bdnf的间充质干细胞作为活性成分的药物组合物 | |
| Branco et al. | Bone marrow mononuclear cells versus mesenchymal stem cells from adipose tissue on bone healing in an Old World primate: can this be extrapolated to humans? | |
| Greco et al. | Characterization of endocannabinoid system and interleukin profiles in ovine AEC: Cannabinoid receptors type-1 and type-2 as key effectors of pro-inflammatory response | |
| CN117545507A (zh) | 生化激活功能障碍骨骼干细胞以实现骨骼再生 |